Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials.
Yasuhiro AsahinaChun-Jen LiuEdward GaneYoshito ItohNorifumi KawadaYoshiyuki UenoJin YounChen-Yu WangJoe LlewellynTakuma MatsudaAnuj GaggarHongmei MoHadas Dvory-SobolGerald CransWan-Long ChuangPei-Jer ChenNobuyuki EnomotoPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2020)
Twelve weeks of treatment with LDV/SOF provides a highly effective and safe treatment for patients with genotype 2 HCV, including those with advanced fibrosis. As a ribavirin-free and protease inhibitor-free regimen with minimal on-treatment monitoring requirements, LDV/SOF can potentially play a crucial role in achieving the WHO's goal of HCV elimination.